Get the Stockscreener App
12.29
0.49%
-0.065
Tango Therapeutics Inc stock is traded at $12.29, with a volume of 245.00K.
It is down -0.49% in the last 24 hours and up +44.08% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$12.35
Open:
$12.22
24h Volume:
245.00K
Relative Volume:
0.07
Market Cap:
$1.65B
Revenue:
$24.30M
Net Income/Loss:
$-145.57M
P/E Ratio:
-9.2368
EPS:
-1.33
Net Cash Flow:
$-149.17M
1W Performance:
-5.53%
1M Performance:
+44.08%
6M Performance:
+78.63%
1Y Performance:
+302.95%
1-Day Range:
$11.93
$12.53
1-Week Range:
$11.93
$13.46
52-Week Range:
$1.03
$13.46
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
12.27 | 1.66B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.44 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.46 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.98 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.86 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.41 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Tango Therapeutics (NASDAQ:TNGX) Sets New 52-Week HighWhat's Next? - MarketBeat
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues - simplywall.st
Analysis Recap: Can Tango Therapeutics Inc be recession proof2025 Sector Review & Stepwise Swing Trade Plans - baoquankhu1.vn
Tango Therapeutics stock hits 52-week high at 12.65 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics stock hits 52-week high at 12.65 USD - Investing.com India
TNGX Analyst Rating Update: Piper Sandler Raises Price Target | TNGX Stock News - GuruFocus
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Nasdaq Futures Research-Driven Model - Kalkine Media
TNGX: Leadership shift supports late-stage trials and robust MTAP-deleted cancer pipeline progress - TradingView — Track All Markets
Tango Therapeutics (NASDAQ:TNGX) Trading 8.3% HigherShould You Buy? - MarketBeat
TNGX: Smooth leadership transition supports late-stage trials in MTAP-deleted cancers and robust 2026 milestones - TradingView — Track All Markets
Sentiment Review: Will Tango Therapeutics Inc stock recover after earningsEntry Point & Intraday High Probability Alerts - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 8.4%What's Next? - MarketBeat
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data - Investing.com Canada
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data By Investing.com - Investing.com India
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 29% - 富途牛牛
Does Tango Therapeutics’ (TNGX) CEO Transition Clarify or Complicate Its Precision Oncology Roadmap? - Yahoo Finance
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - Sahm
Can Tango Therapeutics Inc. stock sustain market leadershipJuly 2025 Macro Moves & Weekly Return Optimization Plans - Улправда
How Tango Therapeutics Inc. stock reacts to oil prices2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Tango Therapeutics Appoints Dr. Malte Peters as CEO - citybiz
Can Tango Therapeutics Inc. stock resist market sell offsJuly 2025 Macro Moves & Safe Capital Growth Plans - Улправда
Will Tango Therapeutics Inc. stock deliver long term returnsTrade Exit Summary & Daily Price Action Insights - Улправда
Tango Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 8, 2026 - marketscreener.com
Tango Therapeutics' CEO Retires, Successor Appointed; Shares Fall - MarketScreener
Is Tango Therapeutics Inc. stock a defensive play in 2025Dip Buying & Short-Term High Return Ideas - Улправда
Tango Therapeutics announces CEO transition: Barbara Weber to retire, Malte Peters appointed successor - marketscreener.com
Tango Therapeutics appoints Malte Peters as new CEO By Investing.com - Investing.com Australia
Tango Therapeutics appoints new CEO amid leadership transition - TipRanks
Tango Therapeutics appoints Malte Peters as new CEO - Investing.com
Tango Therapeutics Announces Leadership Transition: Barbara Weber, M.D. Becomes Executive Chair as Malte Peters, M.D. Assumes Role of President and CEO - Quiver Quantitative
Tango Therapeutics stock hits 52-week high at $11.21 By Investing.com - Investing.com Nigeria
Tango Therapeutics (NASDAQ:TNGX) Sets New 12-Month HighHere's What Happened - MarketBeat
Tango Therapeutics stock hits 52-week high at $11.21 - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.4%Here's What Happened - MarketBeat
Tango Therapeutics appoints Sung Lee to board of directors By Investing.com - Investing.com Nigeria
Tango Therapeutics adds independent director to strengthen governance - MSN
Tango Therapeutics Appoints Sung Lee to Board of Directors - citybiz
Tango Therapeutics Adds Independent Director to Strengthen Governance - TipRanks
Tango Therapeutics appoints Sung Lee to board of directors - Investing.com
Hindware Home Innovation Limited Reaches Critical Trendline SupportStraddle and Strangle Trades & Low Risk Investment Plans - earlytimes.in
Tango Therapeutics (NASDAQ:TNGX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Nasdaq index Notes Liquidity Move - Kalkine Media
Tango Therapeutics Advances TNG462 Study for MTAP-deleted Tumors - MSN
Patterns Watch: How Tango Therapeutics Inc stock reacts to oil pricesDip Buying & Safe Entry Point Identification - moha.gov.vn
Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why - MSN
3 Stocks With Strong Upside Potential for 2026 Gains - Tokenist
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026 - Investing.com
Certain Common Stock of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Pre-Funded Warrants of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.22%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):